159 related articles for article (PubMed ID: 7553690)
1. Human tumor vaccines go molecular. Summary of American Association for Cancer Research Symposium, March 20,1995.
Berd D; Parmiani G
Cancer Immunol Immunother; 1995 Sep; 41(3):199-200. PubMed ID: 7553690
[No Abstract] [Full Text] [Related]
2. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma.
Yeh S; Karne NK; Kerkar SP; Heller CK; Palmer DC; Johnson LA; Li Z; Bishop RJ; Wong WT; Sherry RM; Yang JC; Dudley ME; Restifo NP; Rosenberg SA; Nussenblatt RB
Ophthalmology; 2009 May; 116(5):981-989.e1. PubMed ID: 19410956
[TBL] [Abstract][Full Text] [Related]
3. Melanoma, vitiligo, and uveitis.
Albert DM
Ophthalmology; 2010 Mar; 117(3):643-4; author reply 644. PubMed ID: 20189042
[No Abstract] [Full Text] [Related]
4. T cell-defined melanoma antigens: toward a tumour-specific immunotherapy of the disease.
Parmiani G
Melanoma Res; 1993 Dec; 3(6):391-3. PubMed ID: 7909243
[No Abstract] [Full Text] [Related]
5. Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy.
Benlalam H; Labarrière N; Linard B; Derré L; Diez E; Pandolfino MC; Bonneville M; Jotereau F
Eur J Immunol; 2001 Jul; 31(7):2007-15. PubMed ID: 11449353
[TBL] [Abstract][Full Text] [Related]
6. Cancer immunotherapy with MAGE antigens.
Coulie PG
Suppl Tumori; 2002; 1(4):S63-5. PubMed ID: 12415826
[No Abstract] [Full Text] [Related]
7. Tumor antigens recognized by T lymphocytes.
Boon T; Cerottini JC; Van den Eynde B; van der Bruggen P; Van Pel A
Annu Rev Immunol; 1994; 12():337-65. PubMed ID: 8011285
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer.
Rosenberg SA
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S2-7. PubMed ID: 10685650
[No Abstract] [Full Text] [Related]
9. The use of melanosomal proteins in the immunotherapy of melanoma.
Kawakami Y; Robbins PF; Wang RF; Parkhurst M; Kang X; Rosenberg SA
J Immunother; 1998 Jul; 21(4):237-46. PubMed ID: 9672845
[TBL] [Abstract][Full Text] [Related]
10. [Cytotoxic T-cell immune response against melanoma antigens].
Ayyoub M
Ann Dermatol Venereol; 1998 Nov; 125 Suppl 2():S34-6. PubMed ID: 9922891
[No Abstract] [Full Text] [Related]
11. Identification of tumor-regression antigens in melanoma.
Kawakami Y; Robbins PF; Wang RF; Rosenberg SA
Important Adv Oncol; 1996; ():3-21. PubMed ID: 8791125
[No Abstract] [Full Text] [Related]
12. Possibilities for active immunotherapy of human cancer.
Hellström KE; Hellström I
Cancer Invest; 1992; 10(4):285-93. PubMed ID: 1378351
[No Abstract] [Full Text] [Related]
13. Immune selection after antigen-specific immunotherapy of melanoma.
Riker A; Cormier J; Panelli M; Kammula U; Wang E; Abati A; Fetsch P; Lee KH; Steinberg S; Rosenberg S; Marincola F
Surgery; 1999 Aug; 126(2):112-20. PubMed ID: 10455872
[TBL] [Abstract][Full Text] [Related]
14. Strategies for immunotherapy of cancer.
Melief CJ; Toes RE; Medema JP; van der Burg SH; Ossendorp F; Offringa R
Adv Immunol; 2000; 75():235-82. PubMed ID: 10879286
[No Abstract] [Full Text] [Related]
15. Melanoma antigens: immunological and biological characterization and clinical significance.
Herlyn M; Koprowski H
Annu Rev Immunol; 1988; 6():283-308. PubMed ID: 3289568
[No Abstract] [Full Text] [Related]
16. Adoptive immunotherapy.
Curti BD
Cancer Chemother Biol Response Modif; 1996; 16():274-84. PubMed ID: 8639385
[No Abstract] [Full Text] [Related]
17. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins PF; Sette A; Appella E; Rosenberg SA
J Immunol; 1995 Apr; 154(8):3961-8. PubMed ID: 7706734
[TBL] [Abstract][Full Text] [Related]
18. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy.
Kawakami Y; Rosenberg SA
Int Rev Immunol; 1997; 14(2-3):173-92. PubMed ID: 9131386
[TBL] [Abstract][Full Text] [Related]
19. Cancer vaccines based on the identification of genes encoding cancer regression antigens.
Rosenberg SA
Immunol Today; 1997 Apr; 18(4):175-82. PubMed ID: 9136454
[No Abstract] [Full Text] [Related]
20. Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide.
Salgaller ML; Weber JS; Koenig S; Yannelli JR; Rosenberg SA
Cancer Immunol Immunother; 1994 Aug; 39(2):105-16. PubMed ID: 7519125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
